Differential Associations of Specific Selective Serotonin Reuptake Inhibitors With Resting-State Heart Rate and Heart Rate Variability: Implications for Health and Well-Being

Imagem de Miniatura
Arquivos
art_KEMP_Differential_Associations_of_Specific_Selective_Serotonin_Reuptake_Inhibitors_2016.PDF (176.7 KB)
Citações na Scopus
29
Tipo de produção
article
Data de publicação
2016
Editora
LIPPINCOTT WILLIAMS & WILKINS
DOI
Indexadores
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Autores
KEMP, Andrew H.
NUNES, Maria A.
DANTAS, Eduardo M.
ANDREAO, Rodrigo V.
MILL, Jose G.
RIBEIRO, Antonio L. P.
KOENIG, Julian
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
PSYCHOSOMATIC MEDICINE, v.78, n.7, p.810-818, 2016
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Objective Debate has focused on the effects of the selective serotonin reuptake inhibitor (SSRI) antidepressants on heart rate (HR) and HR variability (HRV), both of which are predictors of adverse cardiovascular events. Here, we examine the associations between specific SSRI antidepressants and resting state HR (and HRV) after accounting for a host of potential confounding factors using propensity score techniques. Methods Participants included 10,466 not taking antidepressants, 46 participants taking escitalopram, 86 taking citalopram, 66 taking fluoxetine, 103 taking paroxetine, and 139 taking sertraline. HR and HRV (root mean square of successive squared differences, high frequency) were extracted from 10-minute resting-state ECGs. Analyses including propensity score weighting and matching were conducted using R-statistics to control for potentially confounding variables. Results Major findings indicated that users of all SSRI medicationsexcept fluoxetinedisplayed lower HRV relative to nonusers. Users of paroxetine also displayed significantly lower HRV relative to users of citalopram (Cohen's d = 0.42), fluoxetine (Cohen's d = 0.54), and sertraline (Cohen's d = 0.35), but not escitalopram. Although associations were also observed for HR, these were less robust than those for HRV. Conclusions Although paroxetine is associated with decreases in HRV relative to nonusers, as well as users of other SSRI medications, fluoxetine was the only medication not to display significant alterations in HR or HRV. These conclusions are limited by the cross-sectional design and nonrandomized nature of medication prescriptions. Findings highlight the importance of focusing on specific medications, rather than more heterogeneous groupings according to antidepressant action, and may have implications for health and well-being for the longer term.
Palavras-chave
health, heart rate variability, HRV, selective serotonin reuptake inhibitors, SSRIs, well-being
URI
https://observatorio.fm.usp.br/handle/OPI/17148
Referências
  1. Aquino EML, 2012, AM J EPIDEMIOL, V175, P315, DOI 10.1093/aje/kwr294
  2. Brunoni AR, 2013, J AFFECT DISORDERS, V151, P71, DOI 10.1016/j.jad.2013.05.054
  3. Brunoni AR, 2012, BIOL PSYCHIAT, V71, pE27, DOI 10.1016/j.biopsych.2011.08.026
  4. Brunoni AR, 2013, INT J NEUROPSYCHOPH, V16, P1937, DOI 10.1017/S1461145713000497
  5. Cacioppo JT, 2007, HANDBOOK OF PSYCHOPHYSIOLOGY, 3RD EDITION, P1, DOI 10.2277/ 0521844711
  6. Chalmers John A, 2014, Front Psychiatry, V5, P80, DOI 10.3389/fpsyt.2014.00080
  7. Chang JS, 2012, PROG NEURO-PSYCHOPH, V39, P136, DOI 10.1016/j.pnpbp.2012.06.002
  8. Cohen J., 1988, STAT POWER ANAL BEHA
  9. COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155
  10. Colquhoun DM, 2013, MED J AUSTRALIA, V198, P483, DOI 10.5694/mja13.10153
  11. Craig CL, 2003, MED SCI SPORT EXER, V35, P1381, DOI 10.1249/01.MSS.0000078924.61453.FB
  12. Ho DE, 2011, J STAT SOFTW, V42, P1
  13. Glassman AH, 2002, JAMA-J AM MED ASSOC, V288, P701, DOI 10.1001/jama.288.6.701
  14. Hamer M, 2011, EUR HEART J, V32, P437, DOI 10.1093/eurheartj/ehq438
  15. Jordan D, 2005, EXP PHYSIOL, V90, P175, DOI 10.1113/expphysiol.2004.029058
  16. Kemp AH, 2013, INT J PSYCHOPHYSIOL, V89, P288, DOI 10.1016/j.ijpsycho.2013.06.018
  17. Kemp AH, 2010, BIOL PSYCHIAT, V67, P1067, DOI 10.1016/j.biopsych.2009.12.012
  18. Kemp AH, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.01387
  19. Kemp AH, 2014, PSYCHOPHARMACOLOGY, V231, P2281, DOI 10.1007/s00213-013-3374-4
  20. Kemp AH, 2014, AM J PSYCHIAT, V171, P1328, DOI 10.1176/appi.ajp.2014.13121605
  21. Kemp Andrew H, 2015, Front Public Health, V3, P9, DOI 10.3389/fpubh.2015.00009
  22. Kemp AH, 2011, BIOL PSYCHIAT, V69, pE25, DOI 10.1016/j.biopsych.2010.10.035
  23. Lederbogen F, 2001, J CLIN PSYCHOPHARM, V21, P238, DOI 10.1097/00004714-200104000-00018
  24. LEWIS G, 1992, PSYCHOL MED, V22, P465
  25. Licht CMM, 2010, BIOL PSYCHIAT, V68, P861, DOI 10.1016/j.biopsych.2010.06.032
  26. Licht CMM, 2011, BIOL PSYCHIAT, V69, pE27, DOI 10.1016/j.biopsych.2010.12.039
  27. Licht CMM, 2008, ARCH GEN PSYCHIAT, V65, P1358, DOI 10.1001/archpsyc.65.12.1358
  28. Lipsey M, 2001, PRACTICAL METAANALYS
  29. Magni LR, 2013, COCHRANE DB SYST REV, V7
  30. Mavrides N, 2013, DEPRESS ANXIETY, V30, P328, DOI 10.1002/da.22051
  31. McCaffrey DF, 2013, STAT MED, V32, P3388, DOI 10.1002/sim.5753
  32. Mill JG, 2013, REV SAUDE PUBL, V47, P54, DOI 10.1590/S0034-8910.2013047003851
  33. Nunes MA, 2012, REV HCPA, V31, P487
  34. Pacher P, 2004, CURR PHARM DESIGN, V10, P2463, DOI 10.2174/1381612043383872
  35. Pacher P, 1999, CURR MED CHEM, V6, P469
  36. Paraskevaidis Ioannis, 2012, Cardiovasc Hematol Agents Med Chem, V10, P109
  37. del Paso GAR, 2013, PSYCHOPHYSIOLOGY, V50, P477, DOI 10.1111/psyp.12027
  38. Ribeiro AL, 2013, REV SAUDE PUBL, V47, P87, DOI 10.1590/S0034-8910.2013047004406
  39. Richelson E, 2003, J CLIN PSYCHIAT, V64, P5
  40. Richelson E, 1996, J CLIN PSYCHOPHARM, V16, pS7, DOI 10.1097/00004714-199606002-00002
  41. Roose SP, 1998, AM J PSYCHIAT, V155, P660
  42. Sanchez C, 2014, INT CLIN PSYCHOPHARM, V29, P185, DOI 10.1097/YIC.0000000000000023
  43. Saul J., 1990, PHYSIOLOGY, V5, P32
  44. Schmidt MI, 2015, INT J EPIDEMIOL, V44, P68, DOI 10.1093/ije/dyu027
  45. Smoller JW, 2009, ARCH INTERN MED, V169, P2128, DOI 10.1001/archinternmed.2009.436
  46. Thayer JF, 2006, ANN NY ACAD SCI, V1088, P361, DOI 10.1196/annals.1366.014
  47. Thayer JF, 2009, ANN BEHAV MED, V37, P141, DOI 10.1007/s12160-009-9101-z
  48. Thayer JF, 2010, INT J CARDIOL, V141, P122, DOI 10.1016/j.ijcard.2009.09.543
  49. Tracey KJ, 2002, NATURE, V420, P853, DOI 10.1038/nature01321
  50. van Zyl Louis T, 2008, Biopsychosoc Med, V2, P12, DOI 10.1186/1751-0759-2-12
  51. Whang W, 2009, J AM COLL CARDIOL, V53, P950, DOI 10.1016/j.jacc.2008.10.060

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPS
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/IPq
Artigos e Materiais de Revistas Científicas - HU
Artigos e Materiais de Revistas Científicas - LIM/20
Carregar mais